Related to Japan's Approval of Regnite for RLS Triggers $10M Payment from Astellas to XenoPort

• Japan Clears Novartis’ Tasigna for First-Line Treatment of Ph+ CML
  
• Tolmar Grants Astellas European Rights to Prostate Cancer Therapy in New Territories
  
• Japan Sanctions BI’s Dabigatran for Preventing Stroke or Venous Embolism in AF Patients
  
• Astellas Pays $68M for Rights to Optimer’s Drug for C. Difficile Infection
  
• Astellas Gains Ex-Asia Rights to Aveo's Phase III Cancer Drug
  
• Cell Signaling Technology and Astellas Forge Pact for Cancer Drugs and Diagnostics
  
• Japan Is First Country to Approve Daiichi Sankyo’s Direct Factor Xa Inhibitor
  
• Japan Approves Merck & Co.’s Gardasil, Zolinza, and Cubicin
  
• Japan Approves Novartis’ MS Drug Gilenya and CAPS Treatment Ilaris
  
• Phase III Results Lead Aveo and Astellas to Plan Regulatory Submissions for Tivozanib
  
• Qiagen Signs Two Biomarker Deals and Confirms Japanese Okay for EGFR Companion Dx
  
• Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial in RCC
  
• FDA Clears Astellas’ Myrbetriq for Overactive Bladder
  
• FDA Approves Novartis' Flucelvax
  
• Astellas and Ambit End Leukemia Drug Partnership
  
• Astellas Takes On Dengue with a Little Help from Its Friends
  
• XenoPort Opts into Co-Promotion Deal with GSK for RLS Drug
  
• FDA Approves XenoPort, GSK’s Horizant for Managing Postherpetic Neuralgia
  
• XenoPort and GSK’s Treatment for Restless Legs Syndrome Cleared in the U.S.
  
• Astellas and XenoPort Submit Japanese Filing for RLS Therapy